Before You Blame the Biology, Look at the Program
A lot of microbiome programs don’t fail because the science is impossible. They fail because the scientific architecture was weak before the first serious decision was ever made.
The microbiome field has only produced two FDA-approved microbiota products so far, REBYOTA and VOWST, and both are for recurrent C. difficile. For a field that has spent years talking about breakthroughs in IBD, metabolism, immunity, and personalized health, that is a pretty narrow set of real wins.
That does not mean the science is fake. It means the biology is harder than the field often wants to admit. It is messier, more context-dependent, and much less forgiving. And when the biology is this difficult, the way a program is built starts to matters.
Too many microbiome programs are weak before the study even begins. They may have a platform, a dataset, outside collaborators, an AI layer, or a respectable advisory board. What they often do not have is a clear enough disease thesis, a real responder hypothesis, a biomarker strategy that actually helps make decisions, or the right mix of in-house expertise close enough to the scientific choices that shape the whole program.
By the time those weaknesses show up in a disappointing readout, a product story that starts drifting, or a data package that looks rich but does not actually clarify anything, the damage is already done. The money is gone. The time is gone. The team has been working hard, but on a program that was never built tightly enough to give clean answers in the first place.
Companies know their platform before they know their biological problem
This is one of the most common structural weaknesses in the microbiome space.
A company knows what it can measure, sequence, predict, engineer, or screen. It knows the category it wants to play in. It knows what story is likely to sound investable. What it often has not done with enough rigor is define the actual biological problem the program is built around.
Not the market problem. The biological one.
If you are building in ulcerative colitis, Crohn’s disease, metabolic disease, neuroimmune disease, or even broad consumer gut health, the first question is not what your platform can do. The first question is what biological thesis the program is actually testing.
What mechanism do you think matters? Why this disease? Why this patient population? Why would the microbiome be relevant here in a way that is more than generic enthusiasm?
If the disease thesis is vague, everything downstream gets weaker. Cohorts get broader. Endpoints get softer. Biomarker panels get bigger instead of better. Internal disagreement gets mislabeled as “iteration” when it is really a sign that the scientific center of gravity was never clear enough.
This matters because the field’s real clinical success remains very narrow. Recurrent CDI is not ulcerative colitis. It is not Crohn’s disease. It is not metabolic disease. It is not generalized “gut health.” The fact that the only FDA-approved wins remain concentrated in recurrent CDI should have made the field much more disciplined about indication logic than it has been.
A good reminder is Vedanta’s VE202 in ulcerative colitis. In August 2025, the company announced that its Phase 2 study did not meet its primary endpoint. That does not prove a weak disease thesis caused the miss. It does show something important. Once you move from recurrent CDI into a heterogeneous immune-mediated disease, the translational burden rises fast, and broad category thinking stops being good enough.
Too many studies start without a real responder hypothesis
The field loves the language of precision. Personalized. Context-dependent. Tailored. Host-microbe specific.
Then a lot of programs turn around and build cohorts as if patients are interchangeable.
If you do not know who the biologically plausible responder is before the study begins, then the study is already carrying unnecessary risk. That does not mean you need perfect certainty. It means you need a real logic.
What kind of patient is most likely to show a signal? What baseline biology matters? What inflammatory state matters? What medications confound the question? What tissue context matters? What microbiome state matters?
Too many studies still enroll broad disease labels and hope the data will sort the rest out later. Then the signal is muddy, the subgroup story appears after the fact, and the field acts as if post hoc cleanup is the same thing as real precision.
It isn’t.
Ulcerative colitis is not one biology. Crohn’s disease is not one biology. Metabolic dysfunction is not one biology. Even within a formal diagnosis, patients differ in inflammatory tone, barrier function, medication exposure, diet, disease duration, microbial ecology, tissue state, and host response. If your cohort is biologically mixed in the wrong way, you can wash out a real signal before the study ever has a chance to succeed.
A lot of microbiome failure may not be a microbiome failure at all. It may be a responder-logic failure.
A biomarker panel is not a biomarker strategy
This is another place where programs look more sophisticated than they are.
It is easy to collect biomarkers. It is easy to list them. It is easy to generate dense-looking data. That is not the same thing as having a biomarker strategy.
A biomarker strategy answers a harder question: what decision is this marker supposed to change?
Is it defining the cohort? Identifying likely responders? Clarifying mechanism? Supporting a go or no-go call? Interpreting the readout? Strengthening an endpoint?
If the answer is vague, then the biomarker is probably playing a decorative role rather than a strategic one.
The microbiome field is especially vulnerable here because it can generate a lot of beautiful data without necessarily getting better at decision-making. Taxa, pathways, metabolites, diversity metrics, inflammatory markers, functional predictions, machine-learned clusters. You can build a very rich story while still not knowing what part of that story should change a scientific or product decision.
Partial expertise is one of the quiet reasons programs get weak
A lot of microbiome companies have smart people. Some have very smart people. That is not the issue.
The issue is whether the right kinds of expertise are actually inside the operating structure and close enough to the scientific decisions to matter.
A bioinformatician is not a disease biologist.
A microbial geneticist is not a mucosal immunologist.
A GI physician is not automatically a microbiome ecologist.
A product lead is not a translational scientist.
A machine-learning team is not a biological reasoning engine.
And yet a lot of programs are built as if adjacent expertise is good enough.
Usually, it isn’t.
If you are building in a specific disease area, you need people who understand that disease deeply enough to challenge the biology, the cohort, the endpoints, and the assumptions. If you are building in the microbiome, you also need people who understand microbial ecology, host-microbe biology, gut context, and microbiome methods deeply enough to know when the scientific story is becoming thinner than the output suggests.
Those roles are not interchangeable. One strong person does not cover all of them. One consultant does not solve them. One famous outside name does not operationalize them.
A lot of programs do not fail because nobody is smart. They fail because critical scientific questions do not belong to anyone with enough depth and enough authority.
Borrowed scientific credibility is not the same thing as internal depth
This is a distinction the field still does not take seriously enough.
External collaborators can be excellent. Advisors can be useful. Outside labs can generate strong science. None of that is the problem.
The problem starts when external science is doing work that the internal team should be able to do itself.
A respected collaborator does not automatically strengthen internal decision-making. A strong paper does not mean the internal biological reasoning is strong. A famous advisor does not mean the company has the right in-house depth. A vendor can produce clean outputs and still leave the core scientific logic weak.
That distinction matters because a lot of companies look stronger from the outside than they are from the inside. They can point to credible science around them, but that is not the same as having the right people in the room when the company decides what to build, what to measure, what to say, what to recommend, and what counts as a real signal.
Consumer-facing companies can be especially exposed here.
ZOE, for example, publicly promotes its “50 good” and “50 bad” microbes framework and ties that framing to its microbiome ranking and test outputs. That may be effective communication. It is also a serious simplification of a context-dependent biological system. Public framing that clean requires strong internal judgment about where simplification becomes distortion.
That is not a small issue. In a consumer setting, weak biological grounding does not just affect a manuscript. It affects how people think about their bodies, what they buy, what they fear, and what they believe a microbiome test can actually tell them.
AI can scale analysis. It cannot create judgment where none exists.
The microbiome field is now layering AI and machine learning on top of all of this. That can be useful. It can also make weak programs more dangerous.
AI can rank patterns. Surface associations. Integrate datasets. Retrieve literature faster than humans can.
It cannot tell you whether the disease thesis is coherent. It cannot tell you whether the cohort is mixed in the wrong way. It cannot tell you whether a biomarker is decision-grade or just convenient. It cannot tell you whether a recommendation is biologically responsible. It cannot substitute for disease expertise, microbial ecology, mucosal immunology, or translational judgment.
Jona is a good example of the AI-forward version of this problem. Its public materials say its AI compares microbiome data against tens of thousands of peer-reviewed papers to identify associations and generate actions. That may sound sophisticated, and parts of it may well be. But the hard question is not whether the system can find literature-linked patterns. The hard question is who inside the company has enough biological and clinical depth to decide what should and should not become action.
A model can help organize information. It cannot replace scientific reasoning.
Just because you can predict does not mean you should recommend.
Stronger programs do something different
The strongest programs do not start with output. They start with pressure.
They pressure-test the disease thesis before the study begins. They ask whether the responder logic is real. They ask whether the biomarkers will change a decision. They ask whether the internal team actually covers the biology being claimed. They ask whether the program is stronger in activity than in coherence.
In other words, they challenge the architecture before they scale the effort.
That is not glamorous. It can slow momentum in the short term. But it prevents a much more expensive kind of delay later, when the company realizes the program was active, funded, and scientifically underbuilt all at once.
A stalled microbiome program rarely looks stalled at first
That is one reason so many teams miss it.
It can look like:
a study that keeps getting revised because the endpoint logic is not settled
a biomarker plan that keeps expanding because nobody knows which signals matter
a product story that sounds clearer than the biology
a dataset that is rich but not decision-useful
internal disagreement that is really a sign of missing scientific ownership
growing dependence on outside experts because the internal bench is thin where it matters
By the time a company realizes these are not isolated annoyances, they often reflect a deeper issue. The scientific program was never built tightly enough to support clean decisions.
The cost of getting this wrong is not abstract
Weak scientific architecture does not just produce messy science. It produces strategic damage.
You burn money on studies that were too broad to answer the question. You invest in biomarkers that do not guide action. You let teams work hard on a program that is never sharp enough to support the next step. You ask data to solve problems that belonged upstream in biology and design. You lose clarity. Sometimes you lose credibility.
In this field, that cost can get brutal.
In 2023, Finch stopped its Phase 3 CP101 trial, laid off about 95% of staff, and shifted toward asset sales. In 2022, Kaleido shut down after multiple setbacks. Those cases do not prove team composition caused the outcomes. They do show what happens when microbiome translation goes sideways for long enough. The cost is not theoretical.
The companies that get this right do one thing earlier
They stress-test the scientific program before weak assumptions harden into studies, product decisions, or claims.
They do not wait for the readout to disappoint. They do not wait for the biomarker package to turn muddy. They do not wait until the story has become stronger than the biology.
They ask harder questions earlier.
If any of this sounds familiar, that is usually the point where outside scientific pressure-testing helps
If your company is building in the microbiome and any of this feels familiar, that is often a sign that the scientific program needs a harder, earlier stress test.
I work with microbiome and health companies on scientific strategy, disease thesis, responder logic, biomarker and endpoint thinking, team-depth evaluation, translational framing, and whether a program is actually built tightly enough to support the decisions it is trying to make.
If that is a problem your team is dealing with, my consulting work is here: